Documents in Process

This case highlights a diagnostic challenge in a 63-year-old female with mild cognitive impairment (MCI) and an arteriovenous malformation (AVM) in the right parieto-occipital brain region. While the patient exhibited minor memory deficits with preserved daily function, a tau-PET scan using [18F]PI-2620 was performed to evaluate possible underlying tauopathy. [...]

This case study reports a diagnostically complex scenario involving a 77-year-old female who initially presented with mild memory complaints. Over the course of one year, she exhibited significant cognitive decline, with MMSE scores dropping from 27/30 to 20/30. [...]

Epstein–Barr virus (EBV) infects approximately 90–95% of the global population1,2 and persists in B cells as a lifelong infection3. Previous EBV infection is associated with autoimmune and neoplastic disease4. [...]

Today, flickering full-field visual stimulation is used to increase neuronal oscillations for a variety of research or therapeutic purposes. We propose spatially organized sequential visual flickering stimulation as a newer tool to circumvent the intrinsic low-pass filter nature of the vertebrate visual system, in order to increase the power of high frequency oscillations in the visual system. [...]

Coronary artery disease (CAD), peripheral arterial disease (PAD), and ischemic stroke (IS) are the principal manifestations of atherosclerotic cardiovascular diseases (ASCVDs). Here we systematically explored the shared and distinct genetic underpinnings of these ASCVDs.SNP-based heritability estimates were calculated using GCTA-GREML in a subset of the UK Biobank, where 8000 controls and equally sized cases were randomly selected for the three ASCVDs separately. [...]

Inhibition of terminal complement activation is an effective therapeutic strategy for acetylcholine receptor antibody-positive generalized myasthenia gravis (gMG) and aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), but it increases the risk of invasive meningococcal infections. Consequently, vaccination against meningococcal serogroups A, C, W, Y, and B is mandatory for all patients receiving complement inhibitors. [...]

The HERMES-24 score recently demonstrated high accuracy for outcome prediction after large vessel occlusion (LVO) treatment in late time window patients from randomized clinical trials. In this study, we externally validate the score in a real-world patient cohort.Data from German Stroke Registry patients with LVO treated with endovascular therapy beyond 6 hours from symptom onset or last seen well were used. [...]

Understanding and modulating memory functions in older adults continues to be a fundamental challenge for neuroscientific research. Given age-associated declines in long-range connectivity, network approaches targeting these connections are of particular interest. [...]

Subtle symptoms, like subjective cognitive decline (SCD) and minor neuropsychological deficits (MNPD), can improve the risk stratification in preclinical Alzheimer´s disease (AD) but their importance is insufficiently elaborated.We pooled data from cognitively normal individuals participating in three longitudinal cohort studies (N = 13,192, 8,359[63.3%] female, mean [SD] age 71.0[8.4]).Compared to participants without SCD and MNPD (SCD-/MNPD-), SCD-/MNPD+, SCD+/MNPD-, and SCD+/MNPD+ participants had an increased risk for mild cognitive impairment (MCI) and dementia, including in amyloid-positive individuals. Focusing on SCD+/MNPD+ participants triples the positive predictive value of amyloid biomarker testing for the 5-year prediction of MCI and reduces the required samples size for trials in preclinical AD to one fourth, compared to considering all cognitively normal participants regardless of subtle symptoms.SCD and MNPD offer a powerful approach for risk stratification in preclinical AD, which can improve clinical trial designs, risk counseling, and future case identifications for early treatment..

GBA1 variants are common genetic risk factors for Parkinson's disease and also for dementia with Lewy bodies. New evidence highlights the relationship between the different GBA1 variants and their associated clinical presentation and disease progression, although penetrance is low and the majority of carriers do not develop a synucleinopathy. [...]